Prelude, Esprit lead further $13.25m "B" funding round in Newnham

Prelude Trust plc (PDT.L), the investment trust specialising in early stage, tech-based businesses, and its manager Esprit Capital Partners, have led an extended "B" series funding round of $13.25m for network graphics chip specialist Newnham Technology Inc.

Prelude has also added the company to its portfolio, investing $3.5m (£1.9m) in the Palo Alto, California headquartered firm which has its main R&D and product development activities in Cambridge (working under the Newnham Research Ltd moniker). Prelude now has a 13.5% shareholding in Newnham.

Newnham is a fabless semiconductor company providing solutions for networking and/or connecting multiple displays to laptops and PCs.

Existing investors Atlas Venture and Benchmark Capital also participated in the funding round.

New board member

Esprit Capital Partners' Alan Duncan (pictured), who has joined Newnham's board said, "Newnham's NIVO (Network In, Video Out) technology establishes a new standard for interactive true-colour networked displays seamlessly extending the rich PC user experience to multiple wire and wireless displays on a network.

"Newnham's first application for its NIVO technology in USB-based products has attracted considerable industry interest and can be found in the latest universal docking stations being sold by Kensington, a leading computer peripherals company."

Mr Duncan said this deal was the first investment where Prelude and Esprit have teamed up to lead a major new financing round for a later stage company. Esprit is the new independent venture capital fund manager created by the merger in June of the Prelude Ventures and Cazenove Private Equity teams. It has $500m of assets under management (including Prelude Trust plc and the Esprit Capital I fund). He said they have been tracking Newnham's progress for more than a year.

Recently appointed Newnham CEO Hamid Farzaneh said the company's technology was well positioned to become the de facto standard for display networking and connectivity.

This funding, which takes the total raised since it was founded three years ago to $21.75m, will allow the firm to expand operations and accelerate new generations of its technology, enabling it to establish a leading position in a number of major new high volume markets, he said.

Recruiting

The Cambridge R&D facility is currently recruiting engineers. In a report in electronicsweekly.com on Tuesday Mr Farzaneh said that “One of the things that is a limit to our growth is our ability to attract talent.

"We are currently hiring aggressively, with about a dozen positions open in Cambridge - most of them are for software and hardware engineers. We have a very high standard and do not want to lower the bar,” he told the website.

He said that if staff could not be found in Cambridge the firm would recruit elsewhere and transfer people in.

Prelude Trust's share price was unchanged by midday at 110p, delivering a market capitalisation of around £42m.

19th July, 2006

Previous articles
CSR confident in face of US patent lawsuit against key customers
Grow your own companies: EEDA’s Big Fish program is a tailored approach to ‘economic gardening’
Briefs: Agilent, Spirent join CSR in EGPS Forum; Stem Cell Sciences launches iStem
CSR turns in record Q3 results but says Q4 sales will be lower
Plasmon's losses widen but new product sales grow
Plasmon in rescue talks with US private equity firm; may lead to takeover
Private investment in stem cell research stalled; patent applications in China soar: Marks & Clerk
Alizyme pumps up R&D spending as 2006 shapes as its pivotal year
ARM reports small growth in 1H08 revenue, slip in pretax profit in tough market conditions; market warms to outlook
Pain drug M6G might 'transform' CeNeS in '06 as development costs widen losses
Subscribe

 

Corporate profiles

 • Abingworth Management


Claire Wilkinson
General Counsel


Abingworth is a long-established venture capital firm specialising in investment in life science biomedical companies. With offices in London, Cambridge, Menlo Park and Boston, Abingworth is active on both sides of the Atlantic and has backed more than 90 developing life science/medical businesses.

[Abingworth Management's profile]


Top20 Index




Currently: 71.78


Create Publisher Site
This Publisher Website ( slot3.siliconfenbusiness.com ) does not exist in Direct-Link-Ads.com. Please create it now.